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GranulomaOleoma is a non-allergic, foreign body type granulomatous reaction. It appears as response to oily exogenous sub-
stances injected to the dermis or subcutis for aesthetical purposes. Treatment for localized lesions is surgical.
When they are multiple, steroids may show some result.
Newer therapeutic possibilities are being introduced and colchicine constitutes an alternative that is ﬁnancially
accessible and safe in moderate doses for certain dermatological illnesses. We present two women with oleoma
on the legs treatedwith oral colchicine. This option was due to the extension of the clinical picture, which would
not have a good surgical outcome. There was signiﬁcant improvement in one patient, while we had to interrupt
the medication in the other because of side effects.
© 2015 Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open access article underua Dona Mariana 143/C-32,
mos-e-Silva).
f Women's Dermatologic Society. Thisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Oleoma is characterized by a non-allergic, foreign body type granu-
lomatous reaction, as response to injection of exogenous oily substances
(mineral, vegetable, or animal oil) into the dermis or subcutaneous tis-
sue, for aesthetic purposes (Magrin et al., 2010). The clinical picture is
characterized by tumors or hardened plaques at the oily injection
sites, sometimes with presence of ﬁstules, purulent material secretion
or ulcerations with release of oily material (Di Benedetto et al., 2002).
Treatment is unsatisfactory and inmost cases, surgical. New therapeutic
possibilities, however, have been introduced.We report the cases of two
womenwhowere diagnosed as oleoma and treatedwith oral colchicine
with very different outcomes.
Case Reports
Case 1
47-year-old black woman, born and living in Rio de Janeiro, labora-
tory technician, complaining of pruriginous lesions in the lower limbs
evolving for about four years. The patient denied triggering factors
and previous treatments. She referred to pain and edema during the
pre-menstrual cycle.In the past pathological history, there was hyperthyroidism treated
with radioactive iodine 2 years before; cutaneous tuberculosis 31
years ago, with regular treatment and surgical excision of one of the
submandibularmasses. She denied other diseases andmedication aller-
gies. Her mother had hypothyroidism and a sister, vitiligo.
Four inﬁltrated hyperpigmented plaqueswere observed at examina-
tion,with centrifugal growth and yellowish surface in themedial region
of the right lower limb, and inﬁltrated hyper chromic plaques, coales-
cent, slightly atrophic, in the medial region of the lower left limb
(Figs. 1 and 2).
Histopathology presented granulomatous hypodermatitis with
gigantocytic reaction of the foreign body type, constituting an oleoma-
like picture (Figs. 3–5).
After histopathological result and further investigation, the patient
referred having injected “a strengthening substance into the muscles”
on the lateral face of lower limbs about 30 years ago, without being
able to deﬁne the content or the quantity of the injected substance.
Treatment was initiated with 40mg of prednisone per day, and in ab-
sence of response to themedication after fourweeks;we chose to discon-
tinue it and to begin with oral colchicine administration at 0.5 mg every
12 hours. Presently, it has been used for 7 months, with reduction of the
hyperpigmentation and lesions softening. The patient is being followed
upwith regularly in the ambulatories of dermatology and endocrinology.
Case 2
59-year-old blackwoman, born in Rio de Janeiro and living in Duque
de Caxias, State of Rio de Janeiro, housewife. In 1989, she referred
the onset of painful nodules, with slow evolution, in lower limbsis an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. Case 1 – Nodules and plaques in both legs.
Fig. 3. Case 1 –Histopathology – inﬂammatory inﬁltrate located at the dermo-hypodermal
junction associated to the presence of clear spaces of various sizes (HE, 40X).
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scleroderma and Parry-Romberg syndrome.
She was submitted to three biopsies at different points in time for a
nodular lesion in the thigh, that evidenced chronic inﬂammatory
process with gigantocytic reaction, involving rounded structures, in
midst of connective tissue, compatible with inclusion of silicone. It
was the same aspect as the one in Case 1.
When questioned she reported injection of liquid silicone in the bi-
lateral inguinal region and thighs for aesthetic purposes.
The patient was submitted to partial excision by plastic surgery,
without complications. Due to the extension of the lesions, we began a
conservative treatment with colchicine at 0.5 mg per day, but after
three months, we suspended the medication due to occurrence of very
frequent diarrhea. Presently, she is under follow up in the dermatolog-
ical and rheumatologic ambulatories.
Discussion
Injection of oily substances into the body for increase of structures,
ﬁlling out of imperfections or other aesthetic beneﬁts is an old practice,
used since the beginning of the 19th century (Gersuny, 1900; Quenu
and Perol, 1948). The immediate aesthetic effects from the injection,
such as alterations of contours and volume of certain parts of the
body, stimulate such practice.Fig. 2. Case 1 – Detail of one of the plaques.There are reports in the literature of injections of several types of oils
carried out in multiple parts of the body, such as parafﬁn in face and
penis, mineral oil in breasts, sesame oil in upper members and chest
region, Vaseline in the male and female genital region, besides unspeci-
ﬁed oily substances (as in the case of one of our patients), and silicone
(Eo et al., 2004; Georgieva et al., 2003; Iyengar et al., 2008; Uchida
et al., 2007). The term parafﬁnoma (or lipogranuloma or sclerosing
lipogranuloma) is used when the process involves injection of parafﬁn,
while siliconoma refers to the injection of silicone (Pónyai et al., 2010).
Ramos-e-Silva et al. (Ramos-e-Silva et al., 2012) described a patient
with oleoma in thighs and buttocks, as complication in mesotherapy
with an unknown substance for cellulitis. This aesthetic procedure con-
sists ofmultiple local injections into the dermis and subcutaneous tissue
of small amounts of medications or other compounds, employed in the
treatment of striae, painful syndromes or other illnesses. As happened
with this patient and the two reported in the present article, women
subjected to these procedures rarely volunteer the history of the use
of foreign substances and only conﬁrm it after the material is observed
in the biopsies.
The clinical picture is characterized by tumors or hardened plaques at
the oily injection sites, sometimeswith presence ofﬁstulas, purulentma-
terial secretion or ulcerations with release of oily material (Di Benedetto
et al., 2002). Clinical presentation of our two patients were according to
the description in literature, however without elimination of purulent or
oily contents through the lesions. Clinical diagnosis was more difﬁcult
because the patients did not report the injections before the histopatho-
logic analysis.Fig. 4. Case 1 – Histopathology – Detail of the inﬂammatory inﬁltrate and the clear spaces
of various sizes (HE, 100X).
Fig. 5. Case 1 – Histopathology – Detail of the inﬂammatory inﬁltrate composed of
macrophages and foreign body multinucleated giant cells, some with asteroid cor-
puscles (HE, 100X).
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after the procedure, while the other referred onset after only six
months. There are reports of the latency period between the injection
of the substance and the appearance of the symptoms for a few years
up to 40 years. This timeframe is related to the amount of injected sub-
stance and the amount of adipose tissue present at the location that will
trigger the reaction to the material (Magrin et al., 2010; Di Benedetto
et al., 2002; Pónyai et al., 2010).
The human organism does not have enzymes capable of digesting
oily substances. This entails a granulomatous reaction of the foreign
body type when that type of substance is injected (Eo et al., 2004).
Histopathologically, the destruction of subcutaneous fatty tissue is
observed, with hyaline necrosis in the stromal septum, forming a typical
“Swiss cheese pattern”, with cystic formations of diversiﬁed sizes
corresponding to fat droplets surrounded by endothelial cells or giant
cells, besides eosinophilic collagen tissue, macrophages containing
phagocytes, and inﬁltrates of round cells around blood vessels. The quan-
tity of material injected inﬂuences the initial reaction: high doses lead to
an initial acute reaction, abatingwith time. Later, the reaction to the exog-
enous material becomes chronic fostering a macrophage reaction that
fragments and stores the substance in the cytoplasm, in an attempt tome-
tabolize it. The larger droplets are involved bymulti-nucleated giant cells.
After this process, ﬁbroblasts of the stroma produce collagen ﬁbers that
separate the oily vacuoles (Di Benedetto et al., 2002; Georgieva et al.,
2003; Pónyai et al., 2010). In presence of this chronicity of the acuteFig. 6. Case 2 – Nodules and plaques in both legs.reaction, the sclerosing lipogranuloma appears (Ackerman, 1978; Behar
et al., 1993). Comparatively, parafﬁnomapresents dense inﬂammatory in-
ﬁltrate and less multinucleated giant cells than siliconoma (Uchida et al.,
2007; Schaumburg-Lever and Lever, 1995).
Complicationsmay arise sooner or later, examples ofwhich are an in-
crease of cutaneous sensibility, inﬂammation, dyschromia, hard edema,
sterile abscesses, lymphangitis, ﬁbrosis with functional compromising
of the affected organ, and migration of the oil, which is not only related
to orthostatism, but to the presence of adipose tissue, that may occur
in several directions (Magrin et al., 2010; Di Benedetto et al., 2002;
Pónyai et al., 2010).
Surgical removal is considered the most effective treatment. There
are reports of the use of topic and systemic steroid therapy, with partial
efﬁcacy, especially in cases where the treatment is postponed.
Uchida et al. (Uchida et al., 2007)described a case of facial parafﬁnoma
that showed a moderate response after use of 20 mg prednisolone per
day. Corticosteroids in general constitute the drug of choice in cases
where resection of the entire material is not possible, due to its anti-
inﬂammatory effect and immune modulator. Magrin et al. (Magrin
et al., 2010) chose to use 500mg of tetracycline every six hours, with pos-
terior progressive dose reduction. Those authors decision was based on a
report of a successful case of siliconoma with tetracycline, to avert the
negative effects of a prolonged corticoid therapy. They referred to the
anti-inﬂammatory and immune modulator effect of that medication,
inhibiting neutrophil chemotaxis and granuloma formation.
Ramos-e-Silva et al. (Ramos-e-Silva et al., 2012) reported the treat-
ment of a patient with oleoma frommesotherapy, initially with systemic
corticoid (prednisone), whose gradual dose reduction led to the worsen-
ing of the pruritus and lesions. One year after beginning the symptoms,
the patient still presented a worsening of the picture and very intense
pruritus during attempts for reduction of the prednisone dose. Treatment
with colchicine at 0.5mg per daywas started and, after amonth, a partial
regression of the lesions was observed. In three months, there was total
disappearance of pruritus, only showing atrophic and hyperchromic cica-
tricial lesions at the sites of the former very unaesthetic lesions.
Colchicine has been used in several dermatological problems with
good results, mainly in neutrophilic dermatosis, but without any formal
indication for use in dermatology (Konda and Rao, 2010). Colchicine is a
naturally toxic product whose active principle is extracted from seeds
and stalks of Colchicum autumnale and other plants of the Colchiaceae
family. It was isolated in 1820 by two French chemists, PS Pelletier
and J Caventon. Referred to in literature as being an alkaloid, Konda
and Rao (Konda and Rao, 2010) described it as a substance containing
nitrogen in its structure, thus erroneously denominated alkaloid, al-
though its biosynthetic forerunner, demecolcine, is an alkaloid. It was
prescribed for the ﬁrst time in 1763 by the Austrian physician Dr.
Anton von Störck, for treatment of an acute gout crisis. It is believed
that Benjamin Franklin introduced it to the US, being himself a patient
of this afﬂiction. Presently, there are two absolute non-dermatological
indications for its use: acute gout crisis and familiar Mediterranean
fever (Konda and Rao, 2010; Bibas et al., 2005).
Colchicine is capable of interruptingmitosis of plant and animal cells
in vivo and in vitro, by connection of the tubulin dimers, diverting their
transformation into micro tubulins. Without formation of mitotic fuses,
there is nomitosis, because it is suspended in themetaphase, and cellu-
larmobility is altered. The ﬁrst affected cells are thosewith high rates of
mitosis. It reducesmobility, adhesivity, and chemotaxis of polymorpho-
nuclear cells, besides interfering in lysosomal degranulation. It alters the
selectins and intercellular adhesion molecules, inhibiting the activation
of T-lymphocytes and their adhesion to endothelial cells. Its action on
adhesion molecules refers to modiﬁcation of the quantity, quality of ex-
pression and topography of several cell glycoproteins. Another action is
damaging cellular secretion of procollagen, suppressing the basal RNA
level for collagen type 1, and to increase production of collagenase, pro-
moting greater degrading of collagen tissue (Götting et al., 1999; Sabroe,
2003). Its immune suppressive action is entailed by the cell-mediated
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interleucin-1 (IL-1), release of histamine and expression of HLA-DR
are inhibited. Entailed by its capacity for connecting to proteins,
in vitro suppression of parathormone and insulin release and displace-
ment of melanocytes is observed (Konda and Rao, 2010; Bibas et al.,
2005).Much controversy exists in literature aboutwhether these effects
occur in the clinically employed doses.
The main collateral effects from its use refer to the gastrointestinal
tract, through inhibition of mitosis in a mucosa with rapid cell turnover
and increase of the intestinal motility by neural mechanisms. This trig-
gers nausea, vomiting, abdominal pain, and diarrhea. With chronic
use, the results may be suppression of bonemarrowwith agranulocyto-
sis, thrombocytopenia, and aplastic anemia. Also subject to occur are:
myopathy, neuropathy, urticaria, epidermal toxic necrolysis, late cuta-
neous porphyria, azoospermia, and alopecia following 2 to 3 months
of therapy, involving face, armpits and the pubic region (Konda and
Rao, 2010; Bibas et al., 2005).
Colchicine also presents other pharmacological effects, such as
alteration of the neuromuscular function, increase of response to
sympathicomimetic agents, contraction of blood vessels, hypertension by
central vasomotor stimulation, depression of the respiratory center, and re-
duction of body temperature, among others (Roberts and Marrow, 2001).
Konda and Rao (Konda and Rao, 2010) allege that colchicine
constitutes a ﬁnancially accessible and safe alternative in moderate
doses for certain dermatological diseases, such in the initial phase of
leukocytoclastic vasculitis, Sweet's syndrome, and aphtous ulcer, compa-
rable to several other immune suppressive agents, even if not being the
frontline for such illnesses. The optionwith oral colchicine in our patients
was due to the extension of the clinical picture, whichwould not lead to a
satisfactory surgical result. One of the patients reported an improvement
in the hardened aspect of the lesions and reduction of hyperchromia, and
continues the treatment. The other patient presented intolerance and the
use of the medication had to be interrupted.
Conclusion
Oleoma is increasing all over the world due to the indiscriminate
growth of aesthetic procedures. Besides surgical removal of the lesionor lesions, and the use of oral steroids, colchicine is another option
that may help some selected patients.
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